Last update 23 Apr 2026

Shanghai Minwei Biotechnology Co., Ltd

Subsidiary Company|2021|Shanghai Shi, China|
minweibiotech.cn

Overview

Tags

Endocrinology and Metabolic Disease
Cardiovascular Diseases
Nervous System Diseases
Fc fusion protein
siRNA
Synthetic peptide

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease9
Nervous System Diseases2
Top 5 Drug TypeCount
Fc fusion protein4
Synthetic peptide2
siRNA2
Antibody1
Fusion protein1
Top 5 TargetCount
GCGR x GIPR x GLP-1R2
FGF21R x GCGR x GIPR x GLP-1R1
FGF21R x GIPR x GLP-1R1
GIPR x GLP-1R1

Related

12
Drugs associated with Shanghai Minwei Biotechnology Co., Ltd
MWN-101
Target
GCGR x GIPR x GLP-1R
Mechanism
GCGR agonists [+2]
Active Org.
Shanghai Minwei Biotechnology Co., Ltd
Originator Org.
Shanghai Minwei Biotechnology Co., Ltd
Active Indication
Diabetes Mellitus, Type 2 [+1]
Inactive Indication
Sleep Apnea, Obstructive
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
MWN-109
Target
GCGR x GIPR x GLP-1R
Mechanism
GCGR agonists [+2]
Active Org.
Shanghai Minwei Biotechnology Co., Ltd
Originator Org.
Shanghai Minwei Biotechnology Co., Ltd
Active Indication
Obesity [+2]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
MWN105
Target
FGF21R x GIPR x GLP-1R
Mechanism
FGF21R agonists [+2]
Active Org.
Shanghai Minwei Biotechnology Co., Ltd
Originator Org.
Shanghai Minwei Biotechnology Co., Ltd
Active Indication
Obesity [+4]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
18
Clinical Trials associated with Shanghai Minwei Biotechnology Co., Ltd
CTR20260870
/ RecruitingPhase 1
评估MWX401注射液单次皮下注射在中国健康参与者及轻度高血压参与者中的安全性、耐受性、药代动力学及药效学特征的I期临床研究
[Translation] A Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single subcutaneous injection of MWX401 in healthy Chinese participants and those with mild hypertension.
CTR20260203
/ RecruitingPhase 2
评价MWN109片在非糖尿病的超重或肥胖参与者中减重维持的有效性和安全性的多中心、随机、开放Ⅱ期扩展临床研究
[Translation] A multicenter, randomized, open-label phase II extended clinical study evaluating the efficacy and safety of MWN109 tablets in weight loss maintenance in overweight or obese non-diabetic participants.
CTR20254820
/ RecruitingPhase 2
评价MWN109 片在非糖尿病的超重或肥胖参与者中的有效性和安全性的随机、双盲、安慰剂对照的Ⅱ期临床试验
[Translation] A randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy and safety of MWN109 tablets in overweight or obese non-diabetic participants.
100 Clinical Results associated with Shanghai Minwei Biotechnology Co., Ltd
Login to view more data
0 Patents (Medical) associated with Shanghai Minwei Biotechnology Co., Ltd
Login to view more data
100 Deals associated with Shanghai Minwei Biotechnology Co., Ltd
Login to view more data
100 Translational Medicine associated with Shanghai Minwei Biotechnology Co., Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
6
3
Phase 1
Phase 2
3
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free